Figure 2 Comparative milestones in T and B lymphocyte maturation

Slides:

Advertisements

Similar presentations

T cell ontology Penny Morel 5/13/08. General issues Introduce “thymocyte” to replace immature Make definitions more precise. DN1 thymocyte - CD4 - CD8.

Advertisements

DIFFERENTIATION AND MATURATION OF T CELLS IN THE THYMUS.

DIFFERENTIATION AND MATURATION OF T CELLS IN THE THYMUS.

T-cell development central tolerance. The cellular organization of the thymus.

DIFFERENTIATION AND MATURATION OF T CELLS IN THE THYMUS.

Chapter 13 Lymphocyte Maturation and Antigen Receptor Expression

Chapter 8 The Development and Survival of Lymphocytes.

T-cell development in the thymus

Development of B and T lymphocytes

Chapter 9 T-cell Development

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

T cell development.

Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.

Figure 4 Relation of neuropsychological deficits and intrathecal immune cell subsets in GABAB receptor antibody–associated limbic encephalitis Relation.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.

Figure 2 Brain-infiltrating immune cells mainly consist of CD8+ memory T cells Immunofluorescence staining of brain-infiltrating immune cells. Brain-infiltrating.

Figure 1 Effect of DMF therapy on T cell subsets

Figure 1 Integrative model of NMO/SD pathogenesis

Figure 2 Brain biopsy Brain biopsy (A) Double staining with anti-aquaporin-4 (AQP4) antibody (dark green) and Luxol fast blue (blue) is shown. Loss of.

E Proteins Enforce Security Checkpoints in the Thymus

Figure 3 Gene expression in CSF cell pellets

Figure 6 Laquinimod treatment of spontaneous EAE prevents progression and reduces the frequency of Tfh cells Laquinimod treatment of spontaneous EAE prevents.

Development of B and T lymphocytes

Figure 1 GABAB expression in the thymus(A–C) Staining of thymus tissue with anti-cytokeratin (A) and anti-GABAB antibody (B, C double immunofluorescence).

Figure 2 B cell development, tolerance checkpoints, and neuromyelitis optica immunotherapy Antibodies are generated during early B cell development by.

Figure 5 Alemtuzumab-induced changes in the innate lymphoid cell (ILC) compartment Alemtuzumab-induced changes in the innate lymphoid cell (ILC) compartment.

Figure 2 CD4+ and CD8+ T cells accumulate in the CSF in GABAB receptor antibody–associated LE CD4+ and CD8+ T cells accumulate in the CSF in GABAB receptor.

Figure 1 Schematic overview of flow cytometry Schematic overview on the analysis of peripheral immune cells by flow cytometry. Schematic overview of flow.

Figure 1 Evolution of blood cell counts during 18-month treatment and follow-up (A) Mean white blood cell count, (B) mean lymphocyte count, (C) mean eosinophil.

Figure 3 Hypothesized cellular and molecular crosstalk influencing NMO/SD Hypothesized cellular and molecular crosstalk influencing NMO/SD (A) Theoretical.

New Cell Sources for T Cell Engineering and Adoptive Immunotherapy

Figure 2 Cerebral and spinal MRI (A) Restricted diffusion of both optic nerves (arrows) on diffusion-weighted and apparent diffusion coefficient imaging.

Figure 1 The human adaptive immune profile in multiple sclerosis (MS)‏

Figure 4 Aquaporin-4 immunoglobulin G (AQP4-IgG) index in time-matched paired serum-CSF specimens: 3 attack/preattack pairs and 7 bridge/remission pairs.

Fritz Melchers, Antonius G Rolink, Christoph Schaniel Cell

Figure 1 Annual trend in specimen type submitted as first sample for aquaporin-4 immunoglobulin G testing (serum only vs CSF only vs both) from 101,065.

Figure 1 Anti-LINGO-1 (Li81) has no effect on activated T-cell proliferation Anti-LINGO-1 (Li81) has no effect on activated T-cell proliferation (A) Western.

Figure 2 Reduced frequency of central memory CD4 T cells in patients with PML Reduced frequency of central memory CD4 T cells (CD4Tcm) (p < ), naive.

Figure 1 B cells and plasma cells accumulate in the CSF in GABAB receptor antibody–associated LE B cells and plasma cells accumulate in the CSF in GABAB.

Figure 1 Examples illustrating gating strategy for fluorescence-activated cell sorting (FACS)‏ Examples illustrating gating strategy for fluorescence-activated.

Figure 4 Autopsy immunochemistry results

Figure 2 Peripheral blood lymphocyte subset counts during dimethyl fumarate treatment(A) Lymphocyte subsets were obtained at baseline (n = 21) and at month.

Figure 2 Comparison of BAFF levels in controls and patients with MuSK(A) ELISA performed on plasma samples shows higher B cell–activating factor (BAFF)

Figure 1 Examination of MuSK antibody levels and B-cell subsetsFlow cytometric analysis (n = 13) using standardized Human Immunology Project Consortium.

Figure 2 CD4+ T-cell subsets fluorescence-activated cell sorting analysis in peripheral blood mononuclear cells of patients with multiple sclerosis treated.

Figure 1 Distinct cognitive performers present differences in the cell populations of the adaptive immune systemThe profile (cell counts per mL of blood)

Figure 2 Repopulation of CD19+ cells in low and high BSA patients and calculation of the BSA Repopulation of CD19+ cells in low and high BSA patients and.

Figure 2 Evolution of blood cell counts during interleukin (IL)–7 therapy Evolution of blood cell counts during interleukin (IL)–7 therapy The leukocyte.

Figure Avidity of IgG specific for influenza A and B following flu vaccinationAvidity of immunoglobulin (Ig) G specific for influenza A and B before and.

Figure MRI brain comparison prior and after treatment and brain biopsy findings MRI brain comparison prior and after treatment and brain biopsy findings.

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

Figure Clinical course and overview of the treatment protocols♦ = neuroradiologic evidence of new disease activity; ★ = CD19+ reconstitution. Clinical.

Figure Spinal cord imaging (A, B) Sagittal and axial T2-weighted cervical spine MRI demonstrating hyperintensities in the central gray matter of patient.

Figure 3 Fluorescence-activated cell sorting (FACS) employing cells singly transfected with M1-AQP4 or M23-AQP4 or cotransfected with both AQP4 isoforms.

T Cell Receptor δ Gene Rearrangement and T Early α (TEA) Expression in Immature αβ LineageThymocytes: Implications for αβ/γδ Lineage Commitment Anne.

Figure 1 Classical pathway and lectin pathway activity in patients with multifocal motor neuropathy and controls Classical pathway (CP) activity (A) and.

Figure 2 B-cell very late antigen-4 (VLA-4) deficiency reduced CNS accumulation of B cells, but not proinflammatory or regulatory T cells (Treg), in myelin.

Yian Gu et al. Neurol Neuroimmunol Neuroinflamm 2019;6:e521

Ingo Kleiter et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e504

Figure 6 Multiple target epitopes exist in the N-terminal domains of Caspr2 (A) Multidomain deletion constructs of Caspr2 were generated to determine which.

Figure 2 Cell-based assay demonstrating differential binding of AChR antibodies to the adult and fetal receptorsThe fetal (gamma subunit specific) and.

Figure 6 P2Y12 is highly expressed in CD68+ and CD163+ cells during parasitic brain infectionIn a case of Schistosoma mekongi infection, hematoxylin and.

Gitanjali Das et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e453

Figure 3. Sensitivity and specificity of microarray analysis in relation to target number Sensitivity and specificity of microarray analysis in relation.

Figure 4 Cell count of selective immune cell subpopulations during alemtuzumab Cell count of selective immune cell subpopulations during alemtuzumab Absolute.

Figure 1 Numbers/seropositivity rates of IVIg-naive and IVIg-exposed STRATIFY-2 enrollees* = % of enrollment samples, ** = date of IVIg and/or concentration.

Figure 4 Venn diagram for B-cell Sup proteins compared with proteins from exosome-enriched fractions from a human B-cell line Venn diagram for B-cell Sup.

Figure 4 Longitudinal analysis of peripheral immune cell composition Frequency of naive, central memory (Tcm), and effector memory (Tem) CD4 T cells over.

Volume 26, Issue 6, Pages (June 2007)

Presentation transcript:

Figure 2 Comparative milestones in T and B lymphocyte maturation Comparative milestones in T and B lymphocyte maturation (A) T cell development. (B) B cell development. Each lineage is represented with distinguishing markers for corresponding stages, and where cell commitment occurs. Arrows indicate potential points along the development pathway where immune tolerizing interventions might be targeted in neuromyelitis optica/spectrum disorder. CAR = chimeric antigen receptor; CD = class designation marker; CLP = common lymphoid precursor; DN = double-negative thymocyte; DP = double-positive CD4+/CD8+ thymocyte; Ig = immunoglobulin; ImmB = immature B cell; ISP = immature single-positive CD8+ thymocyte; LPreB = large PreB; MatB = mature B cell; PreB = pre-B cell receptor B cell; ProB = progenitor B cell; SP = single positive CD4+ or CD8+ thymocyte; SPreB = small PreB; TcR = T cell receptor; Treg = regulatory T cell. Larry Steinman et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e276 © 2016 American Academy of Neurology